| Literature DB >> 35328133 |
Arnaldo Stanzione1, Roberta Galatola1, Renato Cuocolo2,3,4, Valeria Romeo1, Francesco Verde1, Pier Paolo Mainenti5, Arturo Brunetti1, Simone Maurea1.
Abstract
In this study, we aimed to systematically review the current literature on radiomics applied to cross-sectional adrenal imaging and assess its methodological quality. Scopus, PubMed and Web of Science were searched to identify original research articles investigating radiomics applications on cross-sectional adrenal imaging (search end date February 2021). For qualitative synthesis, details regarding study design, aim, sample size and imaging modality were recorded as well as those regarding the radiomics pipeline (e.g., segmentation and feature extraction strategy). The methodological quality of each study was evaluated using the radiomics quality score (RQS). After duplicate removal and selection criteria application, 25 full-text articles were included and evaluated. All were retrospective studies, mostly based on CT images (17/25, 68%), with manual (19/25, 76%) and two-dimensional segmentation (13/25, 52%) being preferred. Machine learning was paired to radiomics in about half of the studies (12/25, 48%). The median total and percentage RQS scores were 2 (interquartile range, IQR = -5-8) and 6% (IQR = 0-22%), respectively. The highest and lowest scores registered were 12/36 (33%) and -5/36 (0%). The most critical issues were the absence of proper feature selection, the lack of appropriate model validation and poor data openness. The methodological quality of radiomics studies on adrenal cross-sectional imaging is heterogeneous and lower than desirable. Efforts toward building higher quality evidence are essential to facilitate the future translation into clinical practice.Entities:
Keywords: adrenal imaging; evidence-based medicine; methodological quality; radiomics
Year: 2022 PMID: 35328133 PMCID: PMC8947112 DOI: 10.3390/diagnostics12030578
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418
Figure 1Literature search and study selection flow-chart.
Main characteristics of included articles.
| Study ID | Year | Country | Aim | Mean Goal | Study Design | Patient Population (Number of Lesions) | Imaging Modality | Segmentation Method (Software/Algorithm) | Feature Extraction | ML | Features Type |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Akai et al. [ | 2020 | Japan | Detection | Localization of primary aldosteronism | Retrospective | 82 (82) | Unenhanced CT | Semi-automatic, 2D (TexRAD) | TexRAD; | No | First-order |
| Amhed et al. [ | 2020 | USA | Characterization | Prediction of Ki-67 expression in ACC | Retrospective | 53 (53) | Contrast-enhanced CT | Manual, 3D (AMIRA) | PyRadiomics | No | Shape-based, first- and higher-order |
| Ansquer et al. [ | 2020 | France | Characterization | Biological and genetic profiling of pheo | Retrospective | 49 (52) | 2-[18F]FDG PET/CT | Automatic, 3D (STAPLE) | Image Biomarker Standardization Initiative | No | Higher-order |
| Chen et al. [ | 2018 | USA | DD | Benign vs. malignant | Retrospective | 222 (222) | Unenhanced and contrast-enhanced CT | NR | NR | Yes (Bayesian classifier) | NR |
| Daye et al. [ | 2019 | USA | Prognosis | Local progression and survival in ablated adrenal metastasis | Retrospective | 21 (21) | Contrast-enhanced CT | Manual, 3D (NR) | MATLAB | Yes (support vector machine) | Higher-order |
| Elmohr et al. [ | 2019 | USA | DD | Adenoma vs. ACC | Retrospective | 54 (54) | Unenhanced and contrast-enhanced CT | Manual, 3D (AMIRA) | PyRadiomics | Yes (random forest) | Shape-based, first- and higher-order |
| Ho et al. [ | 2019 | USA | DD | Benign vs. malignant | Retrospective | 20 (23) | Unenhanced and contrast-enhanced CT and MRI 3T or 1,5T T1 IN-OUT | Manual 3D (Seg3D) | Image Biomarker Standardization Initiative | No | First- and higher-order |
| Koyuncu et al. [ | 2018 | Turkey | DD | Benign vs. malignant | Retrospective | NR (114) * | Unenhanced and contrast-enhanced CT | Semi-automatic, 2D | MATLAB | Yes (neural network) | First- and higher-order |
| Li et al. [ | 2017 | USA | DD | Benign vs. malignant | Retrospective | 223 (230) | Unenhanced CT | Manual, 2D (NR) | NR | Yes (Bayesian) | Higher-order |
| Li et al. [ | 2018 | USA | DD | Benign vs. malignant | Retrospective | 204 (210) | Unenhanced and contrast-enhanced CT | Manual, 2D (NR) | NR | Yes (Bayesian) | Higher-order |
| Li et al. [ | 2020 | USA | DD | Benign vs. malignant | Retrospective | 204 (210) | Unenhanced and contrast-enhanced CT | Manual, 2D (NR) | NR | Yes (Bayesian) | Higher-order |
| Liu et al. [ | 2020 | China | DD | Adenoma vs. pheo | Retrospective | 58 (60) | MRI 3T | Manual, 3D | MaZda | Yes (support vector machine) | First-order |
| Nakajo et al. [ | 2017 | Japan | DD | Benign vs. malignant | Retrospective | 31 (35) | 2-[18F]FDG PET/CT | Semi-automatic, 3D (Advantage Windows Workstation) | Python # | No | First-order |
| Romeo et al. [ | 2018 | Italy | DD | Adenoma vs. non-adenoma | Retrospective | 60 (60) | MRI 3T T1 IN-OUT, T2w | Manual, 3D (3D Slicer) | 3D Slicer | Yes (decision tree) | First- and higher-order |
| Shi et al. [ | 2019 | China | DD | Benign vs. malignant | Retrospective | 225 (265) | Unenhanced and contrast-enhanced CT | Manual, 2D (TexRAD) | TexRAD; | Yes | First-order |
| Schieda et al. [ | 2017 | Canada | DD | Adenoma vs. RCC metastasis | Retrospective | 39 (44) | MRI 3T or 1.5T | Manual, 2D (Image J) | Image J | No | First-order |
| Shoemaker et al. [ | 2018 | USA | DD/Characterization | Benign vs. malignant; calcified vs. non calcified; functioning vs. non functioning | Retrospective | 356 (379) | Unenhanced CT | NR | NR | Yes | First- and higher-order |
| Tu et al. [ | 2018 | Canada | DD | Adenoma vs. lung cancer metastasis | Retrospective | 61 (76) | Contrast-enhanced CT | Manual, 2D | ImageJ | No | First-order |
| Umanodan et al. [ | 2016 | Japan | DD | Adenoma vs. pheo | Retrospective | 47 (52) | MRI 3T | Manual, 2D | Synapse Vincent | No | First-order |
| Wang et al. [ | 2019 | China | Prognosis | Survival in primary adrenal non-Hodgkin’s lymphoma | Retrospective | 19 (19) § | 2-[18F]FDG PET/CT | Manual, 3D | LifeX package | No | First- and higher-order |
| Werner et al. [ | 2016 | Germany | Prognosis | Disease progression and survival in ACC | Retrospective | 10 (10) | 2-[18F]FDG PET/CT | Manual, 3D | Interview Fusion | No | First- and higher-order |
| Yi et al. [ | 2018 | China | DD | Adenoma vs. pheo | Retrospective | 108 (110) | Unenhanced CT | Manual, 2D | MaZda | Yes | First- and higher-order |
| Yi et al. [ | 2018 | China | DD | Adenoma vs. pheo | Retrospective | 265 (265) | Unenhanced and contrast-enhanced CT | Manual, 2D | MaZda | No | First- and higher-order |
| Yu et al. [ | 2020 | USA | DD | Benign vs. malignant | Retrospective | 125 (125) | Contrast-enhanced CT | Manual, 2D (TexRAD) | TexRAD, | No | First-order |
| Zhang et al. [ | 2017 | China | DD | Adenoma vs. pheo | Retrospective | 155 (164) | Unenhanced and contrast-enhanced CT | Manual, 2D (TexRAD) | TexRAD, | No | First-order |
* reported number of images. # formulas reported in the article. § patients with adrenal and/or kidney lymphoma included. ACC: adrenocortical carcinoma, DD: differential diagnosis of adrenal masses, Pheo: pheochromocytoma, NR: not reported.
Figure 2Count plot showing studies published per year.
Radiomics Quality Score (RQS) assessment for all included articles.
| Study ID | Item 1 | Item 2 | Item 3 | Item 4 | Item 5 | Item 6 | Item 7 | Item 8 | Item 9 | Item 10 | Item 11 | Item 12 | Item 13 | Item 14 | Item 15 | Item 16 | Total | (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Akai et al. [ | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 1 | 1 | 0 | 0 | −5 | 0 | 0 | 0 | 0 | 1 | 3% |
| Amhed et al. [ | 1 | 0 | 0 | 0 | −3 | 0 | 0 | 1 | 1 | 0 | 0 | −5 | 0 | 0 | 0 | 0 | −5 | 0 |
| Ansquer et al. [ | 1 | 1 | 0 | 0 | 3 | 1 | 1 | 1 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 12 | 33% |
| Chen et al. [ | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 6 | 17% |
| Daye et al. [ | 1 | 0 | 0 | 0 | −3 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 2 | 6% |
| Elmohr et al. [ | 1 | 1 | 0 | 0 | 3 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 11 | 31% |
| Ho et al. [ | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | −5 | 0 | 0 | 0 | 0 | 0 | 0% |
| Koyuncu et al. [ | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 6 | 17% |
| Li et al. [ | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 6 | 17% |
| Li et al. [ | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 7 | 19% |
| Li et al. [ | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | −5 | 0 | 0 | 0 | 0 | −1 | 0 |
| Liu et al. [ | 1 | 1 | 0 | 0 | 3 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 9 | 25% |
| Nakajo et al. [ | 1 | 0 | 0 | 0 | −3 | 0 | 0 | 1 | 1 | 0 | 0 | −5 | 0 | 0 | 0 | 0 | −5 | 0 |
| Romeo et al. [ | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 10 | 28% |
| Shi et al. [ | 1 | 1 | 0 | 0 | 3 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 9 | 25% |
| Schieda et al. [ | 1 | 0 | 0 | 0 | −3 | 1 | 0 | 0 | 1 | 0 | 0 | −5 | 0 | 0 | 0 | 0 | −5 | 0 |
| Shoemaker et al. [ | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 8 | 22% |
| Tu et al. [ | 1 | 0 | 0 | 0 | −3 | 0 | 0 | 1 | 1 | 0 | 0 | −5 | 0 | 0 | 0 | 0 | −5 | 0 |
| Umanodan et al. [ | 1 | 1 | 0 | 0 | −3 | 0 | 0 | 1 | 1 | 0 | 0 | −5 | 0 | 0 | 0 | 0 | −4 | 0 |
| Wang et al. [ | 1 | 0 | 0 | 0 | 3 | 1 | 0 | 1 | 1 | 0 | 0 | −5 | 0 | 0 | 0 | 0 | 2 | 6% |
| Werner et al. [ | 1 | 0 | 0 | 0 | −3 | 1 | 0 | 0 | 1 | 0 | 0 | −5 | 0 | 0 | 0 | 0 | −5 | 0 |
| Yi et al. [ | 1 | 1 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | −5 | 0 | 0 | 0 | 0 | 1 | 3% |
| Yi et al. [ | 1 | 1 | 0 | 0 | 3 | 0 | 0 | 1 | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 10 | 28% |
| Yu et al. [ | 1 | 0 | 0 | 0 | −3 | 0 | 0 | 1 | 1 | 0 | 0 | −5 | 0 | 0 | 0 | 0 | −5 | 0 |
| Zhang et al. [ | 1 | 0 | 0 | 0 | −3 | 0 | 0 | 1 | 1 | 0 | 0 | −5 | 0 | 0 | 0 | 0 | −5 | 0 |
Figure 3Distribution of RQS percentage score of the papers included in our review. This is presented both as a histogram (bars) and its corresponding density function (line).
Figure 4Line plot depicting the median RQS percentage score in relation to publication year.